ReviewMolecular medicine reports2021

A combination of PD‑1/PD‑L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review).

Xianbin Kong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.